ASCO22: Kidney Cancer research by Toni Choueiri, MD
New data on adjuvant pembrolizumab after kidney cancer surgery presented by Dana-Farber's Toni Choueiri, MD, at #ASCO22 . KEYNOTE-564 shows prolonged distant metastasis-free survival and clinically relevant time to subsequent anticancer therapy and 2nd disease progression.
during escort 2022 I had the pleasure on behalf of my colleague to present updated results about new endpoints from keynote 564. Keynote 564 is a large adjuvant clinical trial that was initially presented at the 2021 sq meeting in the plenary session and published in the new England Journal of Medicine. This study randomized patient with high risk renal cell cancer of clear cell type to receive a year of Pemba realism or placebo actually. And the study met its primary endpoint of disease free survival and liberalism are currently is approved for the treatment of such patients during 2022 S. Co we presented data on distant metastasis free survival in the intention to treat population and the time that we also presented time to first subsequent anticancer therapy and we presented data on the time to second disease progression. These other endpoints are very important besides disease free survival, especially that the overall survival endpoint is not yet mature and both three endpoint distant metastasis free survival, time to first subsequent anti cancer therapy and time to second disease progression were highly statistically significant and clinically relevant and that's consistent with the primary analysis of disease free survival and further support the use of adjuvant embolism after an effect to me as a standard of care with patients with localized reno south cancer at increased risk of recurrence
